December 17, 2019
Roche buys Spark Therapeutics for $4.3 billion
Swiss-based Roche’s is buying Spark Therapeutics for of $114.50 per share in cash, total $4.3 billion through its fully owned subsidiary 022019 Merger Subsidiary.